4 completed, 2 recruiting, 1 terminated, 1 unknown. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Small Fiber Neuropathy: new trials by email Literature Review of Small Fiber Neuropathy trials Research Report on Small Fiber Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) ST-503, Sham (No Treatment) - Chronic Neuropathic Pain | Phase 1 / Phase 2 | Recruiting | Sangamo Therapeutics | 27 | 2025-12-04 | 2026-06-01 |
| IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies Panzyga IVIG, Placebo - Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy | Phase 2 | Recruiting | Endeavor Health | 20 | 2023-12-15 | 2026-01-09 |
| Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration Nicotinamide riboside, Placebo Oral Tablet - Small Fiber Neuropathy | Phase 2 | Completed | Johns Hopkins University | 45 | 2020-09-01 | 2024-06-12 |
| IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3 Intravenous immunoglobulin, 0.9% Sodium Chloride - Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 20 | 2018-09-01 | 2023-09-13 |
| Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy BIIB074, Placebo - Small Fiber Neuropathy, Diabetes Mellitus | Phase 2 | Terminated | Biogen | 265 | 2018-05-31 | 2021-05-05 |
| A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy VX-150, Placebo - Small Fiber Neuropathy | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 89 | 2017-09-20 | 2021-11-15 |
| Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy Intravenous Immunoglobulin, Placebo - Small Fiber Neuropathy | Phase 2 | Completed | Academisch Ziekenhuis Maastricht | 60 | 2016-07-01 | 2019-07-05 |
| Fycompa in Subjects With Small Fiber Neuropathy (SFN) Fycompa, Placebo - Neuropathy, Small Fiber | Phase 2 | Unknown | PNA Center for Neurological Research | 30 | 2016-01-01 | 2016-01-27 |
Diabetes Mellitus (1) · Neuritis (1) · Neuropathy, Painful (1) · Pain (1)
Nervous System Diseases (8) · Neuromuscular Diseases (8) · Peripheral Nervous System Diseases (8) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Neurologic Manifestations (1) · Nutritional and Metabolic Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Immunoglobulins, Intravenous (2) · Sodium Chloride (2) · nicotinamide-beta-riboside (1) · perampanel (1) · salicylhydroxamic acid (1) · vixotrigine (1)
Academisch Ziekenhuis Maastricht (1) · Beth Israel Deaconess Medical Center (1) · Biogen (1) · Endeavor Health (1) · Johns Hopkins University (1) · PNA Center for Neurological Research (1) · Sangamo Therapeutics (1) · Vertex Pharmaceuticals Incorporated (1)
United States (6) · Netherlands (3) · Germany (2) · Italy (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · Hungary (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Ahmet Hoke (1) · Catharina G Faber, MD, PhD (1) · Christopher Gibbons, MD (1) · Lawrence Zeidman, MD, FAAN (1) · Todd Levine, MD (1)
PMID 27439408, PMID 33766992, PMID 37152360
2017 (2), 2015 (1)